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Lithium therapy frequently induces nephrogenic diabetes
insipidus; amiloride appears to prevent its occurrence in
some clinical cases. Amiloride blocks the epithelial sodium
channel (ENaC) located in the apical membrane of principal
cells; hence one possibility is that ENaC is the main entry site
for lithium and the beneficial effect of amiloride may be
through inhibiting lithium entry. Using a mouse collecting
duct cell line, we found that vasopressin caused an increase
in Aquaporin 2 (AQP2) expression which was reduced by
clinically relevant lithium concentrations similar to what is
seen with in vivo models of this disease. Further amiloride or
benzamil administration prevented this lithium-induced
downregulation of AQP2. Amiloride reduced transcellular
lithium transport, intracellular lithium concentration, and
lithium-induced inactivation of glycogen synthase kinase 3b.
Treatment of rats with lithium downregulated AQP2
expression, reduced the principal-to-intercalated cell ratio,
and caused polyuria, while simultaneous administration of
amiloride attenuated all these changes. These results show
that ENaC is the major entry site for lithium in principal cells
both in vitro and in vivo. Blocking lithium entry with
amiloride attenuates lithium-induced diabetes insipidus, thus
providing a rationale for its use in treating this disorder.
Kidney International (2009) 76, 44–53; doi:10.1038/ki.2009.91;
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KEYWORDS: amiloride; aquaporin 2; ENaC; lithium; mCCD; nephrogenic
diabetes insipidus
Lithium is regularly used to treat psychiatric diseases, such as
bipolar disorders, schizoaffective disorders, and depression.
Lithium is prescribed to 0.1% of the population.1 Approxi-
mately 20% of patients develop nephrogenic diabetes
insipidus (NDI), a disorder characterized by polyuria and
polydipsia because of renal insensitivity to the antidiuretic
hormone, arginine vasopressin (AVP).2 Thus, lithium-NDI is
the most common form of NDI. Lithium-NDI patients are at
risk for dehydration-induced lithium toxicity, and prolonged
lithium treatment might lead to end-stage renal disease.1
However, as the symptoms of the underlying psychiatric
disorder have a high impact on the quality of life, cessation of
lithium therapy is not an option for most patients.
The kidney is the main organ for regulating water
homeostasis. In the state of hypernatremia or hypovolemia,
AVP is released from the pituitary gland. Binding of AVP
to the vasopressin type-2 receptor in the basolateral mem-
brane of renal collecting duct principal cells results in the
redistribution of aquaporin-2 (AQP2) water channels from
intracellular vesicles to the apical membrane. Driven by an
osmotic gradient, water will enter the principal cells through
AQP2 and will exit through AQP3 or AQP4 in the basolateral
membrane, resulting in the concentrated urine. Besides this
short-term regulation, AVP also exerts a long-term regulation
by increasing AQP2 expression.3
From studies in rats, it became clear that lithium-NDI
develops in two stages. In the short term (10 days), lithium-
NDI coincides with AQP2 downregulation and natriuresis,
without gross changes in renal morphology.4–6 Chronic
lithium treatment (4 weeks), however, also leads to a severe
decrease in the fraction of principal cells. This is ‘compen-
sated’ by an increase in the fraction of intercalated cells,
which are involved in acid/base balance regulation.7,8
Presently, it is unclear how lithium causes NDI and
whether lithium-NDI can be attenuated. Some data, however,
suggest that lithium may exert its effects by entering principal
cells through the epithelial sodium channel (ENaC). First,
NDI is due to an impaired water reabsorption in the connect-
ing tubules and collecting ducts principal cells,9 where ENaC
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is expressed.10 Second, ENaC has a higher permeability for
lithium than for sodium.11 Third, lithium inhibits amiloride-
sensitive sodium reabsorption in the toad urinary bladder
and rat collecting duct, tissues known to express ENaC,12–14
and the ENaC-blocker triamterene increases lithium excre-
tion.15 Moreover, it was shown in a limited number of
lithium-NDI patients that blocking ENaC with amiloride
significantly reduces urine volume and increases urine
osmolality.16–18 The decreased urine volume is classically
explained by an amiloride-induced hypovolemia, followed by
an increased proximal sodium and water retention. The
increased urine osmolality was suggested to be caused by an
amiloride-induced reduction of sodium reabsorption.16,17
On the basis of the above, we hypothesized that lithium
enters the principal cells through ENaC and that blocking
ENaC by amiloride would reduce cellular entry of lithium,
AQP2 downregulation, and alterations in the cellular
composition of the collecting duct and the lithium-NDI
phenotype.
RESULTS
mCCDc11 cells as a model for lithium-NDI
To study the role of ENaC in lithium-NDI in vitro, a cell line
needs to show (1) expression of all three ENaC subunits, (2)
amiloride-inhibitable transcellular sodium transport, (3)
deamino-8-D-arginine vasopressin (dDAVP)-induced expres-
sion of AQP2, and (4) lithium-induced downregulation of
AQP2.
mpkCCDcl4 cells show a lithium-induced AQP2 down-
regulation19 and an amiloride-inhibitable transcellular vol-
tage difference. However, immunocytochemistry did not
reveal ENaC expression in these cells (data not shown), in
contrast to the novel mouse cortical collecting duct mCCDc11
cell line.20 Therefore, we tested mCCDcl1 cells as a model. To
test whether dDAVP induces AQP2 expression in these cells,
confluent cells were treated for 1–4 days with 1 nM dDAVP.
Immunoblotting revealed the typical non-glycosylated 29
and complex-glycosylated 40–45 kDa AQP2 bands, besides
a nonspecific band of 35 kDa (Figure 1a). Similar to
mpkCCDc14 cells,
19 maximal expression of AQP2 was
observed after 72–96 h. To have steady AQP2 expression,
cells were therefore treated with dDAVP for 96 h in the
following experiments.
In patients on lithium therapy, the concentration of
lithium isB1 mM in serum and ranges between 1 and 10 mM
in urine.1 To test whether these concentrations affect AQP2
expression, cells were incubated with 1 mM lithium at the
basolateral side and with either 1 or 10 mM lithium at the
apical side for 24 or 48 h. Immunoblotting revealed that
lithium reduced the AQP2 expression in a time- and dose-
dependent manner, with an almost complete absence of
AQP2 after a 48-h incubation in 10 mM lithium (Figure 1b).
This concentration of lithium did not affect cell viability as
indicated by similar coomassie-stained protein levels (Figure
1b) and a consistent transcellular resistance of 41000O/cm2
(data not shown). Together, these data reveal that mCCDcl1
cells are a suitable model to investigate the role of ENaC in
lithium-NDI.
The role of ENaC in AQP2 downregulation and transcellular
lithium transport
ENaC is located in the apical membrane of collecting duct
and mCCDc11 cells,
20 and its activity is blocked by amiloride.
To test whether ENaC mediates AQP2 downregulation by
lithium, mCCDc11 cells were treated for 48 h with lithium at
only the basolateral (1 mM) or the apical (10 mM) side with or
without amiloride. Application of lithium at the apical side
reduced AQP2 expression to B30% of control values, which
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Figure 1 | mCCDc11 cells: a proper cell model to study lithium-NDI. (a) mCCDc11 cells were grown to confluence, treated for the indicated
times (in hours) with 1 nM dDAVP, and subjected to AQP2 immunoblotting or, after blotting, stained with coomassie blue. Non-glycosylated
(29 kDa) and complex-glycosylated (40–45 kDa) forms of AQP2, and an a-specific band of 35 kDa, are detected. (b) mCCDc11 cells grown as
previously described were treated for 96 h with 1 nM dDAVP, and for the last 24 or 48 h, in the absence () or presence of 1 mM lithium at the
basolateral side and 1 or with 10 mM lithium at the apical side. Cells were lysed and immunoblotted for AQP2. Blots were also stained with
coomassie blue. Molecular masses (in kDa) are indicated on the left. The signals for non-glycosylated and complex-glycosylated AQP2 were
densitometrically quantified and normalized for coomassie blue staining. Mean values of normalized AQP2 expression per condition are
given as the percentage of control (±s.e.m.) and were determined from three independent filters per condition. Significant differences
(Po0.05) from control () are indicated by an asterisk.
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was prevented by amiloride (Figure 2a). In contrast, the
addition of lithium with or without amiloride to the
basolateral compartment did not change AQP2 levels. Similar
results were obtained with another ENaC blocker, benzamil
(Figure 2b).
If ENaC is the main entry site for lithium, cellular uptake
of lithium and the lithium-induced downregulation of
AQP2 should be influenced by the sodium concentration.
In pilot experiments, mCCDc11 cells were grown in medium
containing lower concentrations of sodium at the apical side
for variable time periods. Incubation of the cells for 12 h
in medium containing 60, 90, or 150 mM sodium showed
similar AQP2 expression, whereas lower concentrations of
sodium or more prolonged incubations resulted in the
reduction of AQP2 expression (data not shown). Therefore,
we incubated the cells with lithium for 12 h in the presence
of 150, 90, or 60 mM sodium. Indeed, the AQP2
expression negatively correlated to the sodium concentration
(Figure 2c), thus confirming competition between sodium
and lithium, and indicating that lithium enters the cells
through a sodium-transporting protein.
If ENaC is the apical entry site for lithium, amiloride
should reduce transcellular transport and the intracellular
concentration of lithium. To test this, cells were treated with
10 mM lithium at the apical side with or without amiloride.
After 24 h, we observed a significant decrease in the lithium
concentration at the apical side and an increase at the
basolateral side, indicating that transcellular lithium trans-
port occurred, which was inhibited by co-incubation with
amiloride (Figure 3a). We next determined intracellular
lithium levels. A 24-h incubation of cells with 1 mM lithium
at the basolateral side resulted only in an intracellular lithium
concentration of 3±3 pmol lithium per mg protein, which
corresponds to a [Liþ ]i of 0.7 mM (Figure 3b). This is well
above that of control cells (below detection limit; data not
shown), indicating that some lithium enters the cells from the
basolateral side. Intracellular lithium concentrations were
markedly higher when 1 or 10 mM lithium was also added
to the apical side, resulting in concentrations of 3.0 and
26.0 mM, respectively. In the presence of amiloride, intra-
cellular lithium concentrations were reduced by more
than 75%. To determine whether the obtained data were cell
line-specific, we repeated some of the above experiments
in mpkCCDcl4 cells. In these cells, amiloride also reduced
the intracellular lithium concentration and prevented
lithium-induced downregulation of AQP2 (Supplementary
Figure S1).
Together, these data indicate that ENaC is the main
cellular entry site for lithium in collecting duct cells and that
blocking ENaC by amiloride prevents lithium-induced
downregulation of AQP2.
Effects of lithium and amiloride on ENaC subunit expression
In vivo, it has been shown that lithium treatment results in
the ENaC downregulation.21 To see whether similar effects
occurred in vitro, mCCDc11 cells were treated with lithium for
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Figure 2 | ENaC blockers reduce lithium-induced AQP2 downregulation in mCCDc11 cells. (a) Confluent mCCDc11 monolayers were
treated for 96 h with 1 nM dDAVP and incubated for the last 48 h in the absence () or presence (þ ) of lithium and/or with 10 mM amiloride
as indicated. At the basolateral and apical side, 1 and 10 mM lithium were used, respectively. (b) Confluent mCCDc11 monolayers were
treated described earlier with 10 mM lithium with/without 10 mM benzamil (Liþ Ben) at the apical side for the last 24 h. (c) mCCDc11cells were
grown as previously described and treated for the last 12 h in medium containing a lower sodium chloride concentration at the apical side
only, with or without lithium (indicated). (a–c) Cells were lysed and immunoblotted for AQP2. Molecular masses (in kDa) are indicated on the
left. Semiquantification of the AQP2 signals, normalization, and statistical analysis were carried out as described in the Figure 1 caption.
Mean values were determined from three independent filters per condition. Significant differences (Po0.05) are indicated by an asterisk.
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12–48 h. Indeed, lithium reduced the expression of b-ENaC,
but not of a- or g-ENaC (Figure 3c). However, these cells
showed an amiloride-dependent transcellular voltage (data
not shown), indicating that ENaC was still functionally
expressed. Amiloride partially prevented the downregulation
of b-ENaC (Figure 3d).
Effects of lithium and amiloride on GSK3b
Rao et al.22 showed a decreased glycogen synthase
kinase (GSK)3b activity in lithium-treated rats, suggesting a
possible involvement of GSK3b in the pathway leading
lithium-NDI. To test whether GSK3b is also involved in the
lithium-induced downregulation of AQP2, total GSK3b
expression and the extent of GSK3b-inactivating phos-
phorylation at Ser9 were analyzed in conjunction with
AQP2 expression. Although lithium treatment for 48 h
again caused downregulation of AQP2, it did not change
total GSK3b expression levels, but strongly increased the
Ser9 phosphorylation of GSK3b (Figure 4a). Zinc also
inhibits GSK3b,23 and BIO-Acetoxime is a specific GSK3
inhibitor.24,25 Indeed, similar to lithium, 20 mM, but not 1 mM,
zinc reduced AQP2 levels and increased phosphorylated
GSK3b, but did not affect total GSK3b levels (Figure 4a). In
line with an important role of GSK3b in AQP2 expression,
BIO-Acetoxime also decreased the expression of AQP2
(Figure 4b).
As amiloride prevents lithium-induced downregulation of
AQP2, we also tested whether amiloride reduced the effect of
lithium on GSK3b. Indeed, although amiloride again
protected the lithium-induced downregulation of AQP2, it
did not affect total GSK3b expression, but significantly
reduced the extent of lithium-induced phosphorylation of
GSK3b at Ser9 (Figure 4c).
Together, these data strongly suggest that in mpkCCDcl4
cells, lithium affects AQP2 expression by inactivating GSK3b
through the phosphorylation at Ser9, which is attenuated by
amiloride.
The effect of amiloride on the development of lithium-NDI
in rats
To analyze whether amiloride can prevent the development
of lithium-NDI in vivo, rats were fed on lithium chow for
4 weeks, with or without amiloride, whereas control rats fed
on normal chow. All rats had free access to a salt block
to compensate for the sodium losses that occur in
lithium-NDI.26
As anticipated,7,8 the rats treated with lithium developed
severe polyuria with reduced urine osmolality (Table 1).
Amiloride treatment attenuated this polyuria and increased
urine osmolality compared with lithium only. Serum lithium
concentrations found in the lithium (0.69±0.08 mM) and
lithium–amiloride (0.57±0.08 mM) groups were similar and
in the therapeutic range, whereas serum lithium concentra-
tions in control rats were below the detection limit (0.05 mM;
Table 1). As observed more often,7,27–30 lithium-treated rats
had a slightly lower body weight. We observed no differences
in serum sodium or serum creatinine concentrations.
However, there were differences in the urinary excretion of
the various solutes. Lithium treatment resulted in increased
sodium losses, which was further exaggerated by amiloride,
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Figure 3 | Amiloride blocks lithium transport. mCCDc11 cells were grown as previously described. (a) After a 24-h treatment with 10 mM
lithium with/without amiloride at the apical side, media from the apical and basolateral compartments were collected and lithium
concentrations were determined. (b) mCCDc11 cells were treated for the last 24 h with the indicated concentrations of lithium at the
basolateral (bl) and/or apical (ap) side in the absence or presence of 10 mM amiloride. After 24 h, lithium concentrations were determined.
Intracellular lithium concentrations were corrected for contamination with extracellular lithium and normalized for the amount of protein.
(a,b) The mean lithium concentration ([Liþ ] ±s.e.m. in mM (a) or in pmol/mg protein (b)) was determined from at least three independent
filters per condition. Significant difference *Po0.05. (c) mCCDc11 cells were treated with lithium on the apical (10 mM) and basolateral (1 mM)
side for the indicated time periods, lysed, and analyzed for ENaC subunit expression. (d) mCCDc11 cells were treated as in panel c with or
without amiloride for 24 h and analyzed for b-ENaC. (c and d) Molecular masses (in kDa) are indicated on the left. Significant differences
(Po0.05) from control are indicated by an asterisk.
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confirming the need for the salt block. To investigate whether
there were differences in food intake, the excretion
of potassium and urea was measured. Urinary excretion of
these solutes was numerically, although not significantly,
lower in rats treated with lithium only. In rats treated with
lithium and amiloride, values were similar to controls.
Furthermore, creatinine clearance was lower in lithium-
treated rats than in control rats. This was not the case in the
amiloride–lithium-treated rats.
The effect of amiloride on the renal collecting duct in
lithium-NDI rats
Lithium-NDI is characterized by a decreased fraction of
AQP2-expressing principal cells with a parallel increase of
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Figure 4 | Effects of lithium on GSK3b. Confluent mpkCCDcl4 monolayers were treated for 96 h with 1 nM dDAVP. (a) Cells were treated
with 1 mM lithium at the basolateral side and 10 mM lithium at the apical side, or with 20 and 1 mM zinc at both sides for the last 48 h and
subjected to AQP2, GSK3b, and phospho-GSK3b(Ser9) immunoblotting or, after blotting, stained with coomassie blue. (b) mpkCCDcl4 cells
were treated with a specific GSK3-inhibitor (BIO-Acetoxime) for the last 48 h and subjected to AQP2 immunoblotting. Concentrations are
expressed in nanomolar. (c) Cells were incubated for the last 48 h in the absence or presence of lithium with or without 10 mM amiloride as
indicated. At the basolateral and apical side, 1 and 10 mM lithium were used, respectively. Molecular masses (in kDa) are indicated on the
left. Semiquantification, normalization, and statistical analysis were carried out as described in the legend of Figure 1. Significant differences
(Po0.05) from control are indicated by an asterisk.
Table 1 | Blood and urine parameters
 Li Li + Am
Body weight (g) 287±11 212±7* 232±8*
Plasma osmolality (mOsm) 283±5 304±5* 288±3**
Plasma lithium (mmol/l) / 0.69±0.08 0.57±0.08
Plasma sodium (mmol/l) 141±1 142±2 141±2
Plasma urea (mmol/l) 5.9±0.3 4.0±0.3* 5.6±0.7
Plasma creatinine (mmol/l) 43±3 41±1 41±2
Urine volume (ml/day) 13±2 189±15* 108±24*,**
Urine osmolality (mOsm) 1537±158 98±25* 400±93*,**
Total lithium excretion (mmol/24 h) / 0.38±0.10 0.61±0.10
Total sodium excretion (mmol/24 h) 1.5±0.3 4.7±0.2* 11.4±1.9*,**
Total potassium excretion (mmol/24 h) 3.2±0.5 2.4±0.4 3.0±0.3
Total urea excretion (mmol/24 h) 10.9±0.2 6.8±0.5 8.6±1.3
Osmolar excretion (mOsm/24 h) 18.3±0.2 16.9±0.3 35.4±6.7
Creatinine clearance (ml/min) 0.93±0.05 0.42±0.09* 0.72±0.12
Urea clearance (ml/min) 1.31±0.25 1.20±0.07 1.15±0.17
Lithium clearance (ml/min) / 0.65±0.10 0.98±0.25
Am, amiloride; Li, lithium.
Values are means±s.e.m.
*Significant differences between control () and other groups.
**Significant differences between the lithium (Li) and lithium+amiloride group (Li+Am).
/ Below detection limit.
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H-ATPase-expressing intercalated cells.7 We evaluated the
effect of amiloride treatment on AQP2 and H-ATPase
expression and on the cellular composition in different
regions of the kidney. We observed a significantly reduced
expression of AQP2 in the cortex of lithium-treated animals
(Figure 5; Table 2). Amiloride significantly attenuated this
decrease, but did not restore the AQP2 expression to the level
of untreated rats. Similar results were obtained for the outer
and inner medulla (Table 2). With respect to the expression
of H-ATPase, we noted an increased expression in the cortex
of lithium-treated rats, which was prevented by amiloride
(Figure 5). Similar data were obtained for the outer and inner
medulla (Table 2).
To investigate whether amiloride treatment also affects the
ratio of principal and intercalated cells, kidney sections were
labeled with antibodies against AQP2, H-ATPase, and nuclear
TOTO-3. In agreement with earlier studies7,8 and with the
immunoblot data, lithium treatment resulted in a decreased
density of AQP2-expressing cells and an increased density of
H-ATPase-expressing cells (Figure 6a). Amiloride treatment
attenuated these changes.
We quantified the changes by calculating a principal/
intercalated cell ratio. Lithium treatment significantly
reduced the ratio in the cortex, an effect that was fully
prevented by amiloride (control: 1.72±0.09; lithium:
0.83±0.06; and lithium–amiloride: 1.78±0.15; Figure 6b).40–45
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Figure 5 | Amiloride prevents effects of lithium on AQP2 and
H-ATPase expressions in lithium-NDI rats. Wistar rats were fed
a normal diet (; n¼ 6), a diet containing lithium (Li; n¼ 6), or a
diet containing lithium and amiloride (LiþAm; n¼ 7). After 4
weeks, one kidney was divided in the cortex, outer medulla, and
inner medulla segments and solubilized. An equal amount of
protein of the cortex of each rat was immunoblotted for AQP2,
H-ATPase, or tubulin (indicated). Molecular masses (in kDa) are
indicated on the left.
Table 2 | Effect of amiloride on collecting duct marker protein
expression
AQP2 H-ATPase
 Li Li + Am  Li Li + Am
Cortex 100±6 4±2* 22±4*,** 100±42 303±23* 150±19**
Outer medulla 100±5 30±9* 53±6*,** 100±30 179±17* 121±40
Inner medulla 100±4 6±4* 42±4*,** 100±29 129±13 65±20**
Am, amiloride; Li, lithium.
Mean values (±s.e.m.) are expressed as percentages of the controls.
*Significant differences between control () and other groups.
**Significant differences between the lithium (Li) and lithium + amiloride group
(Li + Am).
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Figure 6 | Amiloride prevents cell conversion in lithium-NDI rats. (a) Of the rats described in the Figure 5 caption, one kidney was
removed and fixed. Cryosections were prepared and incubated with rabbit H-ATPase (green) and guinea pig AQP2 (red) antibodies,
followed by Alexa-488-conjugated goat-anti-rabbit and Alexa-594-conjugated goat anti-guinea pig antibodies. TOTO-3 (blue) was used to
counterstain the sections. Images were produced with confocal laser scanning microscopy. Bars¼ 10 mm. (b) Of 45 defined areas of the
kidney cortex of each control (n¼ 6), lithium (n¼ 6), and lithiumþ amiloride (n¼ 7) rats, cells positive for AQP2 or H-ATPase were counted
and expressed as the ratio of principal and intercalated cells (±s.e.m.) (total cells control (): 1244; Li: 1393; LiþAm: 2064). Significant
differences *Po0.05.
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Similar results were obtained for the outer medulla (control:
2.21±0.15; lithium: 1.02±0.07; and lithium–amiloride:
1.98±0.13) and the inner medulla (control: 2.66±0.56;
lithium: 1.16±0.12; and lithium–amiloride: 1.91±0.07),
indicating that amiloride prevents the change in the ratio
of principal/intercalated cells.
DISCUSSION
mCCDc11 cells are a proper model to study lithium-induced
AQP2 downregulation
A major impediment to the study of lithium-NDI at the
cellular level was the lack of a suitable model. Our study
indicates that mCCDc11 cells are an appropriate model for
the following reasons. First, mCCDc11 cells express all three
ENaC subunits in the apical membrane and show amiloride-
inhibitable sodium transport.20 Second, and similar to
collecting duct cells in vivo, mCCDc11 cells show a dDAVP-
dependent increase in the expression of endogenous AQP2
(Figure 1a). Third, and in line with in vivo findings,5
mCCDc11 cells show a time- and concentration-dependent
decrease in the AQP2 expression in response to
therapeutically relevant lithium concentrations (Figure 1b).
ENaC is the main entry site for lithium and blocking ENaC
prevents lithium-induced GSK3b inactivation and AQP2
downregulation in vitro
With 1 mM lithium added to the basolateral side of mCCDc11
cells, a small but significant increase in the intracellular
lithium concentration was observed (Figure 3b). As the cells
formed a tight monolayer, this indicated that lithium can
enter through a basolateral site. Although the identity of this
entry pathway remains to be established, it did not reduce
AQP2 expression (Figure 2a).
Upon addition of 1 mM lithium to the apical compart-
ment, intracellular lithium concentrations increased about
3.5-fold to 3.0 mM (Figure 3b), which resulted in slightly, but
not significantly, reduced AQP2 levels (Figure 1b). The
addition of 10 mM lithium together with amiloride to the
apical compartment resulted in similar intracellular lithium
concentrations (Figure 3b) and in normal AQP2 levels
(Figure 2a). In contrast, the AQP2 expression was strongly
reduced with 10 mM lithium at the apical side in the absence
of amiloride (Figure 1c), which coincided with an intracel-
lular lithium concentration of 26 mM (Figure 3b). The
observed AQP2 reduction suggests that within 24 h, AQP2
expression is downregulated with a threshold of intracellular
lithium concentrations between 3 and 26 mM, which are
obtained with lithium concentrations of 1 mM at the baso-
lateral side and 10 mM at the apical side. However, at
prolonged incubation times, AQP2 downregulation may be
induced with lower extracellular lithium concentrations, as
illustrated by the reduced AQP2 levels upon incubation with
1 mM lithium for 48 h (Figure 1b). In agreement with an
important role of GSK3b activity in lithium-NDI mice22 and
the protective effect of amiloride on lithium-induced down-
regulation of AQP2, lithium, and also other GSK3b
inhibitors, increased inactivating GSK3b phosphorylation
and downregulation of AQP2 expression in mpkCCDcl4 cells,
which was partially prevented by co-treatment with amiloride
(Figure 4).
The observed intracellular lithium concentration of 26 mM
is higher than the concentration in the extracellular fluid,
which has been observed before.31 Immunocytochemistry did
not show the difference in cell size between lithium-treated
and control cells, and, in similar experiments, intracellular
potassium levels were not different between control, lithium-
and lithiumþ amiloride-treated cells, indicating that this
is not because of an increased intracellular volume in the
lithium-treated cells. More likely, the strong inwardly
directed electrochemical potential for lithium and the fact
that lithium is a poor substitute for sodium with
Na/K-ATPase to be transported to the extracellular fluid32
cause intracellular accumulation of lithium.
Overall, our study provides strong evidence that ENaC is
the major cellular entry pathway for lithium and that
blocking ENaC reduces lithium-induced GSK3b inactivation
and prevents AQP2 downregulation.
Co-treatment with amiloride attenuates lithium-NDI
As reported,5,7 lithium also induced NDI in our experiments,
as indicated by the increased urine volume and decreased
urine osmolality (Table 1). Our data furthermore reveal that
amiloride treatment decreased urine volume and increased
urine osmolality (Table 1). Although these changes point to
a better urine-concentrating ability, the observed changes
could theoretically be due to differences in solute intake or
extracellular volume: an increased solute intake increases
urine volume because of osmotic diuresis, whereas hypovo-
lemia will reduce urine volume and increase urine osmolality.
However, our data clearly indicate that the effects of
amiloride cannot be explained by these factors. First, the
urinary excretion of osmolytes was higher in the amiloride-
lithium group than in the group receiving lithium only.
Second, if anything, volume depletion was more likely to be
present in lithium-only-treated rats as suggested by the lower
body weight, and the reduction in creatinine clearance.
Consistent with this and the protective effect of amiloride
in mCCDc11 cells, rats treated with amiloride and lithium
had significantly increased AQP2 and decreased H-ATPase
expression compared with rats treated with lithium only
(Figures 5 and 6; Table 2), and the lithium-induced change in
the principal/intercalated cell ratio was completely prevented
(Figure 6). Taken together, our data indicate that amiloride
has a protective effect on lithium-NDI development by
preventing the lithium-induced change in the cellular
composition and partial protection of AQP2 downregulation,
leading to a preserved concentrating ability of the collecting
duct.
The complete prevention of the change in the cell ratio
and the partial protection of AQP2 downregulation by
amiloride suggests that AQP2 expression is more sensitive to
lithium than the integrity of the principal cells, which is in
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agreement with the fact that AQP2 downregulation precedes
the fractional decrease in principal cells in lithium-NDI
development.4,8 It furthermore suggests that the used
amiloride concentration did not completely prevent the
deleterious effect of lithium, and it is unclear whether a
residual effect of lithium can explain the fact that the
concentrating ability of amiloride-treated rats is still lower
than in control rats. One explanation for the reduced
concentrating ability is that blockage of sodium reabsorption
by amiloride could lead to a decrease in osmolality in the
interstitium. However, considering the small contribution of
sodium transport through ENaC to the interstitial osmolality,
which is even less when NaCl is given ad libitum as done here,
this is rather unlikely.
Alternatively, this could be due to an incomplete block
of ENaC by amiloride in the kidney or due to cellular
lithium influx through (an) other transporter(s)/channel(s).
Amiloride was added to the food of the rats at a
concentration of 200 mg/kg dry food, which is equivalent
with 5 mg of amiloride. Assuming a volume of distribution of
3.4 l/kg and a t½ of 21 h, and a bioavailability of 10%,33,34
this will lead to a plasma concentration of 3 mM. Amiloride
clearance has been estimated to be about three times the
creatinine clearance,35 leading to a amiloride excretion of
9mmol/day and an end-urine concentration of 84 mM, which,
as the IC50 of amiloride is 0.1–0.5 mM,
36 very likely completely
blocks ENaC. If these calculations hold for our rats, our data
suggest that, in line with our in vitro data, some lithium may
enter principal cells through a protein other than ENaC.
In our lithium-induced NDI rats and as observed by
others,8 we observed an increased expression of H-ATPase,
which can be partly attributed to an increase in the number
of intercalated cells (Figures 5 and 6). It has been suggested
that the observed reduction in AQP2 expression with lithium
is partially due to a loss of principal cells, either by differen-
tiation of principal cells to intercalated cells or by selective
cell death of principal cells.7,8 Occasionally, and as observed
by others,7 we observed cells to stain positive for both AQP2
and H-ATPase, which may suggest that the change of the
principal/intercalated cell ratio in lithium-NDI is (partly) due
to a transition of principal to intercalated cells. However,
the numbers were too low to influence the counting of the
principal/intercalated cell ratio. In line with a loss of principal
cells, Christensen et al.8 found an increased number of
apoptosis-inducing factor-labeled collecting duct cells in the
inner medullary collecting duct after 10 and 15 days of
lithium treatment, suggesting that apoptosis of principal cells
may be involved, at least in part, in the changes in cellular
composition in lithium-induced NDI. However, they also
found an increased proliferation of not only intercalated cells
but also principal cells, and, therefore, the change in cell
composition could be the result of an increased number of
intercalated cells without a loss of principal cells. If so, the
reduced expression of AQP2 could be the result of a
decreased expression per cell only. The exact underlying
mechanism awaits further experiments.
Lithium-NDI also coincides with reduced expression of
urea transporters UT-A1 and UT-B, and Bedford et al.37,38
recently showed that amiloride treatment also significantly
increases UT-A1 expression and conserves the osmotic
gradient compared with rats treated with lithium only.
Considering our data, the changes in UT-A1 expression and
osmotic gradient with lithium and lithium–amiloride,
respectively, could be due to a decreased/increased expression
per cell, but are likely (partially) explained by the changes in
the principal/intercalated cell ratio.
In conclusion, our data reveal that mCCDc11 cells form a
proper model to study lithium-NDI. We show that ENaC
forms the major entry pathway for lithium into principal
cells, and that blocking ENaC with amiloride reduces the
lithium-induced AQP2 downregulation, protects the cellular
composition of the collecting duct, and thereby attenuates
lithium-NDI. As such, our data provide a rationale for the
use of amiloride in treating lithium-NDI patients.
MATERIALS AND METHODS
Cell culture
Mouse mCCDc11 and mpkCCDcl4 cells were essentially grown as
described.20,39 Cells were seeded at a density of 1.5 105 cells/cm2
on semi-permeable filters (Transwell, 0.4 mm pore size; Corning
Costar, Cambridge, MA, USA) and cultured for 8 days. Unless stated
otherwise, the cells were treated for the last 96 h with 1 nM dDAVP to
the basolateral side, to induce AQP2 expression. Lithium and zinc
chloride were administered as indicated. A concentration of 10mM of
amiloride or benzamil, concentrations specifically blocking
ENaC,36,40 were administered to the apical side, unless indicated
otherwise. BIO-Acetoxime (Calbiochem, San Diego, CA, USA) was
used indicated. Medium with reduced sodium concentrations was
prepared identical to the standard medium except that lower
amounts of NaCl were added.
Lithium assays
To determine transcellular lithium transport, mCCDc11 cells were
grown on 1.13 cm2 filters. After 24 h treatment with 10 mM lithium
in the presence or absence of amiloride at the apical side, the
basolateral and apical media were collected and the lithium
concentrations were determined with a flame photometer (Eppen-
dorf 6341, Hamburg, Germany).
Intracellular lithium concentrations were determined essentially
as described.31 Briefly, mCCDc11 cells were grown on 4.7-cm
2 filters.
To determine the extent of lithium contamination from the
extracellular side, fluorescein isothiocyanate dextran (FITC-dextran)
was added to the lithium-containing medium to a final concentra-
tion of 10 mM just before harvesting, after which the medium was
mixed. Then, the filters were washed three times with iso-osmotic
sucrose (pH 7.3) at 4 1C and cells were lysed by sonication in 1 ml
Milli-Q water. Of the 800 ml sample, the amount of lithium was
determined by flame photometry, from which the total amount of
lithium in the sample was calculated.
Of the 100ml sample, the amount of FITC-dextran was measured
using spectrofluorophotometry (Shimadzu RF-5301, Kyobo, Japan)
at 492 nM (excitation) and 518 nm (emission) wavelengths. By
comparing the obtained values with a two-fold FITC-dextran
dilution series, the FITC-dextran concentration in each sample
was determined, from which the extent of extracellular
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Liþ contamination was calculated and subtracted from the total
amount to obtain the intracellular lithium amount. With the used
FITC-dextran concentration, a contamination above 1:5000 would be
detected. To correct for differences in cellular yield, the intracellular
lithium amounts were normalized for the protein amount in each
sample, which was determined using the Bio-Rad Protein Assay
(Munchen, Germany). The intracellular lithium concentration (in
millimolar) was estimated by calculating the cellular water content,
on the basis of the assumption that 20% of the cell weight consists of
cellular proteins and the remaining 80% is water.41
Experimental animals
Male Wistar rats (200–300 g) were obtained from the Animal Facility
of the RUNMC (Radboud University Nijmegen Medical Centre).
The rats were treated with lithium as described.5
Control rats received normal rodent diet (ssniff R/M-H V1534,
ssniff Spezialdiaten GmbH, Soest, Germany; n¼ 6). For lithium
therapy, lithium chloride was added to the chow to give a
concentration of 40 mmol/kg for the first week and 60 mmol/kg
dry food for the next 3 weeks. The rats were then killed (n¼ 6). For
amiloride treatment, amiloride was added to the lithium chow to a
concentration of 200 mg/kg dry food for the entire 4 weeks (n¼ 7).
All rats had free access to water, food, and a sodium-chloride block.7
For the last 48 h of the experiment, the rats were housed in
metabolic cages to measure water intake and urine output during
the last 24 h. All animal experiments were approved by the Animal
Experiments Committee of the RUNMC.
Tissue preparation
Rats were anesthetized with isofluorothane, after which their blood
was removed by a heart puncture. Then, the rats were killed by
cervical dislocation and the kidneys rapidly removed. One kidney
was fixed for immunohistochemistry by immersion in 1% (wt/vol)
periodate-lysine-paraformaldehyde for 2 h and in 15% (wt/vol)
sucrose in phosphate buffered saline overnight, whereas of the other
kidney, the inner medulla, outer medulla, and cortex were dissected
for immunoblotting as described.19
Blood and urine analyses
Blood serum was prepared by 16 h incubation at 4 1C, followed by
centrifugation at 600 g for 2–3 min. Urine was centrifuged at 4000 g
for 5 min to remove sediment. Both serum and urine samples were
analyzed for osmolality, and for sodium and lithium concentrations
by standard procedures of the General Clinical Chemical laboratory
of the RUNMC.
Immunoblotting
mCCDc11 cells from the 1.13 cm
2 filter were lysed in 200 ml Laemmli
buffer and 15 ml samples were analyzed, while 5–10 mg of kidney
material was also analyzed. Polyacrylamide gel electrophoresis,
blotting, and blocking of the PVDF membranes were carried out as
described.42 The membranes were incubated for 16 h with affinity-
purified rabbit AQP2 antibodies (1:3000 dilution),43 affinity-
purified rabbit anti-v1 H-ATPase antibodies (1:2000-dilution; gift
from Dr S Nielsen, Denmark), rabbit anti-Ser9-GSK3b (1:1000
dilution; Cell Signaling Technology, Beverly, MA, USA), mouse anti-
GSK3b (1:5000 dilution; BD Transduction Laboratories, San Jose,
CA, USA), or with mouse anti-tubulin antibodies (1:100,000
dilution; gift from Dr Kreis, Switzerland) in Tris-buffered saline
Tween-20 supplemented with 1% non-fat dried milk. ENaC
detection was carried out as described.20 Blots were incubated for
1 h with goat anti-rabbit IgGs (1:5000) or with goat anti-mouse IgGs
(1:2000) (Sigma, St Louis, MO, USA) as secondary antibodies
coupled to horseradish peroxidase. Proteins were visualized using
enhanced chemiluminescence (Pierce, Rockford, IL, USA). Films
were scanned using a Bio-Rad 690c densitometer and signals were
analyzed using Bio-Rad software. Two-fold dilution series of the
respective proteins were blotted in parallel to allow semi-
quantification. Equal loading of the samples was confirmed by
parallel immunoblotting for tubulin or by staining of the blots with
coomassie blue.
Immunohistochemistry
Immunohistochemical staining was performed on 7-mm-thick
sections of fixed frozen kidney samples, following antigen retrieval.
The sections were blocked in goat serum dilution buffer (GSDB:
16% goat serum, 0.3% Triton X-100, 0.3 M NaCl in phosphate
buffered saline) for 30 min and incubated for 16 h at 4 1C with rabbit
anti-a4 H-ATPase antibodies (1:3000, provided by Dr F Karet, UK).
After washes and incubation with Alexa 488-conjugated goat anti-
rabbit antibodies, the sections were incubated with affinity-purified
guinea pig AQP2 antibodies (1:50)44 for 1 h at room temperature
and with Alexa 594-conjugated goat anti-guinea pig secondary
antibodies (Molecular Probes, Leiden, The Netherlands). TOTO-3
iodide (Invitrogen, Carlsbad, CA, USA) was used for counter-
staining. Images were produced using Bio-Rad MRC-1024 confocal
laser scanning microscopy.
Quantification of principal and intercalated cells was performed
on the confocal images of the fluorescent kidney sections. Tubules in
45 randomly selected areas of each kidney region of each animal
were included. Only cells with distinct TOTO-3 staining were
counted. Cells stained with H-ATPase or AQP2 were considered as
intercalated or principal cells, respectively.
Data analysis
Differences between groups were tested by Student’s t-test corrected
by the Bonferroni multiple-comparisons procedure. Differences
were considered statistically significant for Po0.05.
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